Children's Yale-Brown Obsessive Compulsive Scale modified for pervasive developmental disorders.
OBJECTIVE
To examine the psychometric properties of the Children's Yale-Brown Obsessive Compulsive Scales (CYBOCS) modified for pervasive developmental disorders (PDDs).


METHODS
Raters from five Research Units on Pediatric Psychopharmacology (RUPP) Autism Network were trained to reliability. The modified scale (CYBOCS-PDD), which contains only the five Compulsion severity items (range 0-20), was administered to 172 medication-free children (mean 8.2 +/- 2.6 years) with PDD (autistic disorder, n = 152; Asperger's disorder, n = 6; PDD not otherwise specified, n = 14) participating in RUPP clinical trials. Reliability was assessed by intraclass correlation coefficient (ICC) and internal consistency by Cronbach's alpha coefficient. Correlations with ratings of repetitive behavior and disruptive behavior were examined for validity.


RESULTS
Eleven raters showed excellent reliability (ICC = 0.97). The mean CYBOCS score was 14.4 (+/- 3.86) with excellent internal consistency (alpha = .85). Correlations with other measures of repetitive behavior ranged from r = 0.11 to r = 0.28 and were similar to correlations with measures of irritability (r = 0.24) and hyperactivity (r = 0.25). Children with higher scores on the CYBOCS-PDD had higher levels of maladaptive behaviors and lower adaptive functioning.


CONCLUSIONS
The five-item CYBOCS-PDD is reliable, distinct from other measures of repetitive behavior, and sensitive to change.
Scahill
Lawrence
L
Yale Child Study Center, Yale University, New Haven, CT 06520, USA. lawrence.scahill@yale.edu
McDougle
Christopher J
CJ
Williams
Susan K
SK
Dimitropoulos
Anastasia
A
Aman
Michael G
MG
McCracken
James T
JT
Tierney
Elaine
E
Arnold
L Eugene
LE
Cronin
Pegeen
P
Grados
Marco
M
Ghuman
Jaswinder
J
Koenig
Kathleen
K
Lam
Kristen S L
KS
McGough
James
J
Posey
David J
DJ
Ritz
Louise
L
Swiezy
Naomi B
NB
Vitiello
Benedetto
B
D014150:Antipsychotic Agents / Q000627:therapeutic use*; D000697:Central Nervous System Stimulants / Q000627:therapeutic use*; D002648:Child; D002659:Child Development Disorders, Pervasive / Q000175:diagnosis* / Q000188:drug therapy* / Q000523:psychology; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008774:Methylphenidate / Q000627:therapeutic use*; D009771:Obsessive-Compulsive Disorder / Q000175:diagnosis* / Q000188:drug therapy* / Q000523:psychology; D015203:Reproducibility of Results; D018967:Risperidone / Q000627:therapeutic use*; D012720:Severity of Illness Index; D011795:Surveys and Questionnaires
D014150:Antipsychotic Agents; D000697:Central Nervous System Stimulants; D008774:Methylphenidate; D018967:Risperidone